カレントテラピー　29-10　サンプル page 12/32

このページは カレントテラピー　29-10　サンプル の電子ブックに掲載されている12ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
natriuretic peptide concentration in patients with chronicsymptomatic left ventricular dysfunction. Circulation 96：509 -516, 199712）Anand IS, Fisher LD, Chiang YT, et al：Changes in brainnatriuretic....

natriuretic peptide concentration in patients with chronicsymptomatic left ventricular dysfunction. Circulation 96：509 -516, 199712）Anand IS, Fisher LD, Chiang YT, et al：Changes in brainnatriuretic peptide and norepinephrine over time and mortalityand morbidity in the Valsartan Heart Failure Trial（Val -HeFT）. Circulation 107：1278-1283, 200313）Yanagisawa M, Inoue A, Ishikawa T, et al：Primary structure,synthesis, and biological activity of rat endothelin, anendothelium -derived vasoconstrictor peptide. Proc NatlAcad Sci U S A 85：6964-6967, 198814）Sakurai T, Yanagisawa M, Masaki T：Molecular characterizationof endothelin receptors. Trends Pharmacol Sci 13：103 -108, 199215）Tsutamoto T, Wada A, Maeda Y, et al：Relation betweenendothelin-1 spillover in the lungs and pulmonary vascularresistance in patients with chronic heart failure. J Am CollCardiol 23：1427 -1433, 199416）Neuhold S, Huelsmann M, Strunk G, et al：Comparison ofcopeptin, B -type natriuretic peptide, and amino -terminalpro -B -type natriuretic peptide in patients with chronicheart failure：prediction of death at different stages of thedisease. J Am Coll Cardiol 52：266-272, 200817）Gheorghiade M, Niazi I, Ouyang J, et al：VasopressinV2 -receptor blockade with tolvaptan in patients with chronicheart failure：results from a double -blind, randomizedtrial. Circulation 107：2690-2696, 200318）Nagaya N, Satoh T, Nishikimi T, et al：Hemodynamic, renal,and hormonal effects of adrenomedullin infusion in patientswith congestive heart failure. Circulation 101：498-503, 200019）Kato J, Kobayashi K, Etoh T, et al：Plasma adrenomedullinconcentration in patients with heart failure. J Clin EndocrinolMetab 81：180 -183, 199612892